2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

Demographic and Clinical Characteristics of Flunarizine Induced Parkinsonism: Nationwide Data Between 2000 and 2006 in Taiwan

W. Lin, CY. Wei, HJ. Chen (ChangHua, Taiwan)

Drug-Induced Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Design and Status of the BIIB054 SPARK Trial

Parkinson Study Group, A. Siderowf (NY, USA)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa for Parkinson’s Disease (PD) Patients Experiencing Motor Fluctuations

P. LeWitt, R. Gendreau, J. Meckler, N. Navon (West Bloomfield, MI, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years

R. Ou, Y. Wu, Q. Wei, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system

K. Ikenaka, K. Araki, S. Sonoda, T. Takeuchi, Y. Nagai, Y. Goto, H. Mochizuki (Suita, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Development of evidence-based clinical practice guideline (CPG) of complementary and alternative medicine (CAM) for Parkinson’s disease (PD)

K.H. Cho, S.W. Kwon, S.H. Lee, T.H. Kim (Seoul, Republic of Korea)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Diagnostic potential of automated middle cerebellar peduncle volumetry in variants of multiple system atrophy

F. Krismer, K. Seppi, T. Potrusil, R. Steiger, I. Zucal, G. Göbel, G. Wenning, E. Gizewski, W. Poewe, C. Scherfler (Innsbruck, Austria)

Neuroimaging (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Diagnostic tips from a case series of patients with Late Onset Tay Sachs disease

G.M. Riboldi, K. Anstett, H. Lau (New York, NY, USA)

Rare Genetic and Metabolic Diseases  ·  Hall 3FG